



Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium

Dr Shisong Jiang (CSO and Founder) presents latest development with novel recombinant overlapping peptide (ROP) technology.

Oxford, UK - 27th June 2018 – FOR IMMEDIATE RELEASE



Oxford 27 June 2018; Oxford Vacmedix, the UK based biopharma company focused on the development of a new generation of cancer vaccines, announced today that its novel Recombinant Overlapping Peptide (ROP) technology had been presented at the 2018 Myongji International Cancer Symposium.

The meeting was held in Seoul, South Korea and focused on new horizons in the development of treatments for cancer on immunotherapy and on precision medicine. Other speakers included researchers from the Mayo Clinic and the University of Chicago in the US as well as from St Luke's International hospital in Japan.

Dr. Jiang, CSO and Founder of Oxford Vacmedix (OVM) and a researcher in the Department of Oncology at University of Oxford, presented the role of TNF as a potential target for cancer therapy and the exciting preclinical data of OVM's leading development programmes for two cancer vaccines. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines are being developed as single agents and in combination with immuno-oncology agents. The company will also continue to develop its diagnostic kits for cellular immunity.

William Finch, CEO of Oxford Vacmedix said: "We were very pleased to present ROP technology at this important meeting and to have the opportunity to discuss the novel research and the exciting development programme which could lead to significant benefit for patients with cancer"

Wang-Jun Lee, Chairman of Myongji Hospital Group, added: "We are delighted Dr Jiang could participate in this meeting and we look forward to a productive collaborations with OVM especially in research and in clinical trials. We are confident that we can support the continued growth and development of the company"

ENDS

Oxford Vacmedix UK

Magdalen Centre, Oxford Science Park, Oxford OX4 4GA
T +44 (0)1865 784074 E enquiries@oxfordvacmedix.com

For more information or to arrange an interview, please contact:

William Finch, CEO, Oxford Vacmedix

T: +44 (0)1865 784074 | E: wfinch@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.

For more information, please visit: <http://www.oxfordvacmedix.com/>